Document:

EXHIBIT C

APOLLO
MEDICAL HOLDINGS, INC.

FORM OF INVESTOR WARRANT

 

THESE WARRANTS AND THE SHARES OF COMMON STOCK ISSUABLE UPON
EXERCISE OF THESE WARRANTS HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE "ACT"), OR THE
SECURITIES LAWS OF ANY STATE AND MAY NOT BE OFFERED, SOLD, TRANSFERRED, PLEDGED, HYPOTHECATED OR OTHERWISE DISPOSED OF EXCEPT PURSUANT
TO (i) AN EFFECTIVE REGISTRATION STATEMENT UNDER THE ACT AND ANY APPLICABLE STATE LAWS, (ii) TO THE EXTENT APPLICABLE, RULE 144
UNDER THE ACT (OR ANY SIMILAR RULE UNDER THE ACT RELATING TO THE DISPOSITION OF SECURITIES), OR (iii) AN OPINION OF COUNSEL, IF
SUCH OPINION SHALL BE REASONABLY SATISFACTORY TO COUNSEL TO THE ISSUER, THAT AN EXEMPTION FROM REGISTRATION UNDER THE ACT AND APPLICABLE
STATE LAW IS AVAILABLE.

 

STOCK PURCHASE WARRANT

 

To Purchase _________________________________
Shares of Common Stock

( ______________ shares)

 

	No. 2012-	Issue Date:  _______, 2012

 

THIS CERTIFIES that, for value received,

____________________________________________ ________________________
(the "Holder"), is entitled, upon the terms and subject to the conditions hereinafter set forth, at any time on or after
the date hereof, to subscribe for and purchase, from APOLLO MEDICAL HOLDINGS, INC., a Delaware corporation (the "Company"),
of the fully paid non-assessable shares of the Company's common stock, $0.001 par value per share ("Common Stock") at
a purchase price of $0.45 per share or a lesser price as described in Section 11c, provided that such right will terminate, if
not terminated earlier in accordance with the provisions hereof, at 5:00 p.m. (California time) on January 31, 2018 (the "Expiration
Date").

 

The purchase price and the number of shares for which these
warrants (the "Warrants") is exercisable are subject to adjustment, as provided herein and specifically in Section 11.

 

These Warrants were issued in connection with the Company's
private offering (the "Offering") of units of the Company's securities (the "Units"), each Unit consisting
of $50,000 par value 9% Senior Subordinated Callable Convertible Promissory Notes maturing February 15, 2016 and 37,500 warrants
to purchase one share of the Company's Common Stock until January 31, 2018 (a "Warrant Share"), pursuant to a Private
offering Memorandum dated November ____, 2012 (the "Memorandum") and is subject to the terms of a Subscription Agreement
(the "Subscription Agreement") dated the date hereof to which the initial Holder is a party. Capitalized terms used and
not otherwise defined herein will have the respective meanings ascribed to such terms in the Memorandum.

 

As used herein the following terms, unless the context otherwise
requires, have the following respective meanings:

 

(a) The term "Company" shall include
Apollo Medical Holdings, Inc., f/k/a Silicone Inc. and any corporation that shall succeed or assume the obligations of Apollo Medical
Holdings, Inc. hereunder.

 

(b) The term "Warrant Shares"
includes (i) the Company's common stock and (ii) any other securities into which or for which any of the Common Stock may be converted
or exchanged pursuant to a plan of recapitalization, reorganization, merger, sale of assets or otherwise.

 

    	1

    	 

    

 

(c) The term "Other Securities"
refers to any stock (other than Common Stock) and other securities of the Company or any other person (corporate or otherwise)
which the holder of the Warrant at any time shall be entitled to receive, or shall have received, on the exercise of the Warrant,
in lieu of or in addition to Common Stock, or which at any time shall be issuable or shall have been issued in exchange for or
in replacement of Common Stock or Other Securities.

 

(d) The term "Exercise Price"
shall be $0.45 per share or a lesser price per share as described in Section 11c, subject to adjustment pursuant to the terms hereof.

 

		1.	Number of Shares Issuable upon Exercise.

 

Unless sooner terminated in accordance herewith,
from and after the date hereof through and including the Expiration Date, the Holder shall be entitled to receive, upon exercise
of these Warrants in whole or in part, the number of shares of Common Stock of the Company set forth on the first page of these
Warrants, subject to adjustment pursuant hereto, by delivery of an original or fax copy of the exercise notice attached hereto
as Exhibit A (the "Notice of Exercise") along with payment to the Company of the Exercise Price.

 

		2.	Exercise of Warrant.

 

(a) The purchase rights represented by these
Warrants are exercisable by the registered Holder hereof, in whole at any time or in part from time to time by delivery of the
Notice of Exercise duly completed and executed at the office of the Company in California (or such other office or agency of the
Company as it may designate by notice in writing to the registered Holder hereof at the address of such Holder appearing on the
books of the Company), and upon payment of the Exercise Price of the shares thereby purchased (cash, bank wire transfer, or by
certified or official bank check payable to the order of the Company in an amount equal to the Exercise Price of the shares thereby
purchased); whereupon the Holder of these Warrants shall be entitled to receive a certificate for the number of Warrant Shares
so purchased; provided that the Company will place on each certificate a legend substantially the same as that appearing on these
Warrants, in addition to any legend required by any applicable state or federal law. If these Warrants are exercised in part, the
Company will issue to the Holder hereof a new Warrant upon the same terms as these Warrants but for the balance of Warrant Shares
for which these Warrants remains exercisable. The Company agrees that upon exercise of these Warrants the Holder shall be deemed
to be the record owner of the shares issued upon exercise as of the close of business on the date on which these Warrants shall
have been exercised as aforesaid. These Warrants will be surrendered at the time of exercise or if lost, stolen, misplaced or destroyed,
the Holder will comply with Section 7 below (b) Certificates for shares purchased hereunder shall be delivered to the Holder hereof
within a reasonable time after the date on which these Warrants shall have been exercised as aforesaid.

 

(c) The Company covenants that all Warrant
Shares which may be issued upon the exercise of rights represented by these Warrants will, upon exercise of the rights represented
by these Warrants, be fully paid and non-assessable and free from all preemptive rights, taxes, liens and charges in respect of
the issue thereof (other than taxes in respect of any transfer occurring contemporaneously with such issue which shall be paid
by the Company in accordance with Section 4 below).

 

		3.	No Fractional Shares.

 

The Company shall not be required to issue
fractional Warrant Shares upon the exercise of these Warrants or to deliver Warrant Certificates that evidence fractional Warrant
Shares. In the event that a fraction of a Warrant Share would, except for the provisions of this Section 3, be issuable upon the
exercise of these Warrants, the Company shall pay to the Holder exercising the Warrant an amount in cash equal to such fraction
multiplied by the Per Share Market Value of the Warrant Share.

 

For purposes of these Warrants, the Per
Share Market Value shall be determined as follows: As used herein, "Per Share Market Value" means on any particular date
(a) the closing bid price per share of Common Stock on such date on the national securities exchange on which the shares of Common
Stock are then listed or quoted, or if there is no such price on such date, then the average of the closing bid and asked prices
on the national securities exchange on the date nearest preceding such date, (b) if the shares of Common Stock are not then listed
or quoted on a national securities exchange, the average of the closing bid and asked prices for a share of Common Stock in the
over-the-counter market, as reported by the National Quotation Bureau, Inc., or an equivalent generally accepted reporting service,
at the close of business on such date, or (c) if the shares of Common Stock are not then publicly traded, the fair market value
of a share of Common Stock as determined by an appraiser selected in good faith by the Holders of a majority in interest of the
Warrants then outstanding.

 

    	2

    	 

    

 

		4.	Charges, Taxes and Expenses.

 

Issuance of certificates for Warrant Shares
upon the exercise of these Warrants shall be made without charge to the Holder hereof for any issue or transfer tax or other incidental
expense in respect of the issuance of such certificate, all of which taxes and expenses shall be paid by the Company, and such
certificates shall be issued in the name of the Holder of these Warrants, or in such name or names as may be directed by the Holder
of these Warrants; provided, however, that in the event certificates for Warrant Shares are to be issued in a name other than the
name of the Holder of these Warrants, these Warrants, when exercised, shall be accompanied by the Assignment Form attached hereto
as Exhibit B (the "Assignment Form") duly executed by the Holder hereof; and provided further, that upon any transfer
involved in the issuance or delivery of any certificates for Warrant Shares, the Company may require, as a condition thereto, that
the transferee execute an appropriate investment representation as may be reasonably required by the Company.

 

		5.	No Rights as Shareholders.

 

These Warrants does not entitle the Holder
hereof to any voting rights or other rights as a Shareholder of the Company prior to the exercise hereof.

 

		6.	Exchange and Registry of Warrant.

 

These Warrants is exchangeable, upon the
surrender hereof by the registered Holder at the above-mentioned office or agency of the Company, for a new Warrant or Warrants
aggregating the total Warrant Shares of the surrendered Warrant of like tenor and dated as of such exchange. The Company shall
maintain at the above-mentioned office or agency a registry showing the name and address of the registered Holder of these Warrants.
These Warrants may be surrendered for exchange, transfer or exercise, in accordance with its terms, at such office or agency of
the Company, and the Company shall be entitled to rely in all respects, prior to written notice to the contrary, upon such registry.

 

		7.	Loss, Theft, Destruction or Mutilation of Warrant.

 

Upon receipt by the Company of evidence
reasonably satisfactory to it of the loss, theft, destruction or mutilation of these Warrants, and in case of loss, theft or destruction,
of indemnity reasonably satisfactory to it, and upon reimbursement to the Company of all reasonable expenses incidental thereto,
and upon surrender and cancellation of these Warrants, if mutilated, the Company will make and deliver a new Warrant of like tenor
(but with no additional rights or obligations) and dated as of such cancellation, in lieu of these Warrants.

 

		8.	Saturdays, Sundays, Holidays, etc.

 

If the last or appointed day for the taking
of any action or the expiration of any right required or granted herein shall be a Saturday or a Sunday or shall be a legal holiday,
then such action may be taken or such right may be exercised on the next succeeding day not a Saturday, Sunday or legal holiday.

 

		9.	Cash Distributions.

 

No adjustment on account of cash dividends
or interest on the Company's Common Stock or Other Securities that may become purchasable hereunder will be made to the Exercise
Price under these Warrants.

 

		10.	Consolidation, Merger or Sale of the Company.

 

If the Company is a party to a consolidation,
merger or transfer of assets that reclassifies or changes its outstanding Common Stock, the successor corporation (or corporation
controlling the successor corporation or the Company, as the case may be) shall by operation of law assume the Company's obligations
under these Warrants. Upon consummation of such transaction the Warrants shall automatically become exercisable for the kind and
amount of securities, cash or other assets that the holder of a Warrant would have owned immediately after the consolidation, merger
or transfer if the holder had exercised the Warrant immediately before the effective date of such transaction. As a condition to
the consummation of such transaction, the Company shall arrange for the person or entity obligated to issue securities or deliver
cash or other assets upon exercise of the Warrant to, concurrently with the consummation of such transaction, assume the Company's
obligations hereunder by executing an instrument so providing and further providing for adjustments which shall be as nearly equivalent
as may be practical to the adjustments provided for in this Section 10.

 

    	3

    	 

    

 

		11.	Adjustments in the Exercise Price

 

The number of shares and class of capital
stock purchasable under these Warrants are subject to adjustment from time to time as set forth in this Section 11.

 

(a) Adjustment for change in capital stock.
If the Company:

 

(i) pays a dividend or makes a
distribution on its Common Stock, in each case, in shares of its Common Stock;

(ii) subdivides its outstanding
shares of Common Stock into a greater number of shares;

(iii) combines its outstanding
shares of Common Stock into a smaller number of shares;

(iv) makes a distribution on its
Common Stock in shares of its capital stock other than Common Stock; or

(v) issues by reclassification
of its shares of Common Stock any shares of its capital stock;

 

then the number and classes of shares purchasable upon exercise
of each Warrant in effect immediately prior to such action shall be adjusted so that the holder of any Warrant thereafter exercised
may receive the number and classes of shares of capital stock of the Company which such holder would have owned immediately following
such action if such holder had exercised the Warrant immediately prior to such action.

 

For a dividend or distribution the adjustment
shall become effective immediately after the record date for the dividend or distribution. For a subdivision, combination or reclassification,
the adjustment shall become effective immediately after the effective date of the subdivision, combination or reclassification.

 

If after an adjustment the Holder, upon
exercise of a Warrant, may receive shares of two or more classes of capital stock of the Company, the Board of Directors of the
Company shall in good faith determine the allocation of the adjusted Exercise Price between or among the classes of capital stock.
After such allocation, that portion of the Exercise Price applicable to each share of each such class of capital stock shall thereafter
be subject to adjustment on terms comparable to those applicable to Common Stock in these Warrants. Notwithstanding the allocation
of the Exercise Price between or among shares of capital stock as provided by this Section 11(a), a Warrant may only be exercised
in full by payment of the entire Exercise Price currently in effect.

 

(b) The Company will not, by amendment of
its Articles of Incorporation or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale
of securities or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms to be observed
or performed hereunder by the Company, but will at all times in good faith assist in the carrying out of all the provisions of
this Section 11 and in the taking of all such action as may be necessary or appropriate in order to protect the exercise rights
of the Holders of these Warrants against impairment.

 

		12.	Certificate as to Adjustments.

 

In each case of any adjustment or readjustment
in the shares of Common Stock (or Other Securities) issuable on the exercise of the Warrant, the Company at its expense will promptly
cause its Chief Financial Officer or other appropriate designee to compute such adjustment or readjustment in accordance with the
terms of the Warrant and prepare a certificate setting forth such adjustment or readjustment and showing in detail the facts upon
which such adjustment or readjustment is based, including a statement of (a) the consideration received or receivable by the Company
for any additional shares of Common Stock (or Other Securities) issued or sold or deemed to have been issued or sold, (b) the number
of shares of Common Stock (or Other Securities) outstanding or deemed to be outstanding, and (c) the Exercise Price and the number
of shares of Common Stock to be received upon exercise of these Warrants, in effect immediately prior to such adjustment or readjustment
and as adjusted or readjusted as provided in these Warrants. The Company will forthwith mail a copy of each such certificate to
the Holder of the Warrant and any Warrant agent of the Company (appointed pursuant to Section 16 hereof).

 

    	4

    	 

    

 

		13.	Reservation of Stock Issuable on Exercise of Warrant.

 

The Company will at all times reserve and
keep available, solely for issuance and delivery on the exercise of the Warrant, shares of Common Stock (or Other Securities) from
time to time issuable on the exercise of the Warrant.

 

		14.	Assignment; Exchange of Warrant.

 

Subject to compliance with applicable securities
laws, these Warrants, and the rights evidenced hereby, may be transferred by any registered Holder hereof (a "Transferor")
with respect to any or all of the shares underlying these Warrants. On the surrender for exchange of these Warrants, with the Transferor's
duly executed Assignment Form and together with evidence reasonably satisfactory to the Company demonstrating compliance with applicable
securities laws, which shall include, without limitation, a legal opinion from the Transferor's counsel that such transfer is exempt
from the registration requirements of applicable securities laws, the Company at its expense (but with payment by the Transferor
of any applicable transfer taxes) will issue and deliver to or on the order of the Transferor thereof a new Warrant of like tenor,
in the name of the Transferor and/or the transferee(s) specified in such Assignment Form (each a "Transferee"), calling
in the aggregate on the face or faces thereof for the number of Warrant Shares called for on the face or faces of the Warrant so
surrendered by the Transferor; and provided further, that upon any such transfer, the Company may require, as a condition thereto,
that the Transferee execute an appropriate investment representation as may be reasonably required by the Company.

 

		15.	Registration Rights.

 

The Company has agreed to register the Warrant
Shares in any subsequent registration statement filed by the Company with the SEC, so that Holders shall be entitled to sell the
same simultaneously with and upon the terms and conditions as the securities sold for the Company's account are being sold pursuant
to any such registration statement, subject to such lock-up provisions as may be proposed by the underwriter of said registration
statement (the "Piggyback Registration Right"). There is no guarantee as to a time frame for the filing of such a registration
statement.

 

		16.	Warrant Agent.

 

The Company may, by written notice to each
Holder of a Warrant, appoint an agent for the purpose of issuing Common Stock (or Other Securities) on the exercise of these Warrants
pursuant to Section 2, exchanging these Warrants pursuant to Section 14, and replacing these Warrants pursuant to Section 7, or
any of the foregoing, and thereafter any such issuance, exchange or replacement, as the case may be, shall be made at such office
by such agent.

 

		17.	Notices, etc.

 

All notices shall be in writing signed by
the party giving such notice, and delivered personally or sent by overnight courier or messenger or sent by registered or certified
mail (air mail if overseas), return receipt requested, or by telex, facsimile transmission, telegram or similar means of communication.
Notices shall be deemed to have been received on the date of personal, telex, facsimile transmission, telegram or similar means
of communication, or if sent by overnight courier or messenger, shall be deemed to have been received on the next delivery day
after deposit with the courier or messenger, or if sent by certified or registered mail, return receipt requested, shall be deemed
to have been received on the third business day after the date of mailing. Notices shall be sent to the addresses set forth below
each party's signature on the Subscription Agreement.

 

    	5

    	 

    

 

		18.	Notices of Record Date.

 

In case,

(a) The Company takes a record
of the holders of its Common Stock for the purpose of entitling them to subscribe for or purchase any shares of stock of any class
or to receive a dividend, distribution or any other rights; or

 

(b) There is any capital reorganization
of the Company, reclassification of the capital stock of the Company (other than a subdivision or combination of its outstanding
shares of Common Stock), or consolidation or merger of the Company with or into another corporation which does not constitute a
sale of the Company; or

 

(c) There is a voluntary or involuntary
dissolution, liquidation or winding up of the Company;

 

then, and in any such case, the Company shall cause to be mailed
to the Holder, at least 20 business days prior to the date hereinafter specified, a notice stating the date on which (i) a record
is to be taken for the purpose of such dividend, distribution or rights, or (ii) such reclassification, reorganization, consolidation,
merger, dissolution, liquidation or winding up is to take place and the date, if any is to be fixed, as of which holders of Common
Stock of record shall be entitled to exchange their shares of Common Stock for securities or other property deliverable upon such
reclassification, reorganization, consolidation, merger, dissolution, liquidation or winding up.

 

		19.	Amendments and Supplements.

 

(a) The Company may from time to time supplement
or amend these Warrants without the approval of any Holders in order to cure any ambiguity or to be correct or supplement any provision
contained herein which may be defective or inconsistent with any other provision, or to make any other provisions in regard to
matters or questions herein arising hereunder which the Company may deem necessary or desirable and which shall not materially
adversely affect the interest of the Holder. All other supplements or amendments to these Warrants must be signed by the party
against whom such supplement or amendment is to be enforced.

 

(b) Notwithstanding Section 19(a), the Company
may at any time during the term of these Warrants reduce the then current Exercise Price to any amount and for any period of time
deemed appropriate by the Board of Directors of the Company.

 

		20.	Investment Intent.

 

Holder represents and warrants to the Company
that Holder is acquiring the Warrants for investment and with no present intention of distributing or reselling any of the Warrants.

 

		21.	Certificates to Bear Language.

 

The Warrants and the Warrant Shares issuable
upon exercise thereof shall bear the following legend by which Holder shall be bound:

 

"THE SECURITIES REPRESENTED BY THIS CERTIFICATE
HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. THE SECURITIES MAY NOT BE SOLD OR TRANSFERRED IN THE ABSENCE
OF SUCH REGISTRATION OR AN OPINION OF COUNSEL REASONABLY SATISFACTORY TO THE COMPANY THAT AN EXEMPTION FROM REGISTRATION UNDER
SUCH ACT IS AVAILABLE."

 

Certificates for Warrants or Warrant Shares without such legend
shall be issued if such Warrants or Warrant Shares are sold pursuant to an effective registration statement under the Securities
Act of 1933, as amended (the "Act"), or if the Company has received an opinion from counsel reasonably satisfactory to
counsel for the Company, that such legend is no longer required under the Act.

 

    	6

    	 

    

 

		22.	Miscellaneous.

 

(a) These Warrants shall be governed by
and construed in accordance with the laws of the State of California without regard to principles of conflicts of laws. The parties
submit to the jurisdiction of the Courts of the County of Los Angeles, State of California or a Federal Court empanelled in the
State of California for the resolution of all legal disputes arising under the terms of these Warrants, including, but not limited
to, enforcement of any arbitration award. The Company and the Holder agree to submit to the jurisdiction of such courts and waive
trial by jury.

 

(b) If any action or proceeding is brought
by the Company on the one hand or by the Holder on the other hand to enforce or continue any provision of these Warrants, the prevailing
party's costs and expenses, including its reasonable attorney's fees, in connection with such action or proceeding shall be paid
by the other party.

 

(c) In the event that any provision of these
Warrants is invalid or unenforceable under any applicable statute or rule of law, then such provision shall be deemed inoperative
to the extent that it may conflict therewith and shall be deemed modified to conform with such statute or rule of law. Any such
provision, which may prove invalid or unenforceable under any law, shall not affect the validity or enforceability of any other
provision of these Warrants.

 

(d) The headings in these Warrants are for
purposes of reference only, and shall not limit or otherwise affect any of the terms hereof.

 

IN WITNESS WHEREOF, the Company has caused
these Warrants to be executed by its officers thereunto duly authorized as of the date first written above.

 

	 	APOLLO MEDICAL HOLDINGS, INC.,
	 	a Delaware corporation
	 	 
	 	By: _______________________________
	 	Warren Hosseinion, M.D
	 	Chief Executive Officer

 

    	7

    	 

    

 

EXHIBIT A

TO

WARRANT

NOTICE OF EXERCISE

To Be Executed by the Holder

in Order to Exercise the Warrant

The undersigned Holder hereby elects to
purchase _______ Shares pursuant to the attached Warrant, and requests that certificates for securities be issued in the name of:

__________________________________________________________

(Please type or print name and address)

__________________________________________________________

__________________________________________________________

__________________________________________________________

(Social Security or Tax Identification Number)

and delivered

to:_________________________________________________________________

___________________________________________________________________.

(Please type or print
name and address if different from above)

If such number of Shares being purchased
hereby shall not be all the Shares that may be purchased pursuant to the attached Warrant, a new Warrant for the balance of such
Shares shall be registered in the name of, and delivered to, the Holder at the address set forth below.

 

In full payment of the purchase price with
respect to the Shares purchased and transfer taxes, if any, the undersigned hereby tenders payment of $__________ by check, money
order or wire transfer payable in United States currency to the order of [________________].

 

	 	HOLDER:
	 	 
	Dated:	By:	/s/ 
	 	 	Name
	 	 	Title 

 

    	8

    	 

    

 

EXHIBIT B

TO

WARRANT

FORM OF ASSIGNMENT

(To be signed only on
transfer of Warrant)

For value received, the undersigned hereby
sells, assigns, and transfers unto _____________ the right represented by the within Warrant to purchase ______ shares of Common
Stock of _________, Inc., a Delaware corporation, to which the within Warrant relates, and appoints ____________________ Attorney
to transfer such right on the books of ____________, Inc., a Delaware corporation, with full power of substitution of premises.

 

	Dated:	By:	/s/
	 	 	Name
	 	 	Title
	 	 	(signature must conform to name of holder as specified on the fact of the
Warrant)
	 	 	 
	 	 	Address:

 

Signed in the presence of :

 

Dated:

 

    	9Exhibit 10.24

 

development
collaboration and intellectual properTy AGREEMENT

 

This development
collaboration and intellectual properTy AGREEMENT (“Agreement”) is made as of December 18, 2012
(the “Effective Date”) by and between Aerosonic Corporation, a Delaware corporation (“Aerosonic”)
and LG CNS Co., Ltd., a corporation (“LG CNS”). Aerosonic and LG CNS are collectively referred to herein as
the “Parties” and each individually as a “Party.”

 

Background

 

LG CNS desires to develop an electronic
flight instrumentation system (“EFIS”). Aerosonic has developed an EFIS with characteristics similar to the
requirements of the proposed LG CNS system (the “LG CNS EFIS”). Subject to the conditions set forth in this
Agreement, Aerosonic desires to sell to LG CNS, and LG CNS desires to purchase from Aerosonic, the EFIS Technology to assist with
LG CNS’s development of the LG CNS EFIS.

 

As set forth in this Agreement, Aerosonic
has also agreed to provide certain services to LG CNS related to the development of the LG CNS EFIS.

 

Agreement

 

The Parties agree as follows:

 

Development
Collaboration Services.

 

Initial
Support for the Development of LG CNS EFIS. Aerosonic will support development of the
LG CNS EFIS with one (1) engineering representative of mutually agreed qualifications at LG CNS’s office located at Seoul,
Korea for a twelve (12) month period, which will begin on a mutually agreed date, not before the Transfer Date (as defined below).
The person assigned to this role may change over the course of the year based on mutual agreement of qualifications and project
requirements or circumstances impacting the assigned individuals. This engineering representative’s compensation and expenses
(to the and on the conditions determined by Aerosonic) will be the responsibility of Aerosonic. This engineering representative
will work at the direction of LG CNS in support of activities relating to and appropriate to the development of the LG CNS EFIS.

 

Additional
Support Services; Statements of Work.
Aerosonic will supply such additional support as may be requested on a time and materials basis pursuant to Statements of Work
entered into as set forth in this Section 1.2. No Statement of Work shall be effective unless signed by duly authorized
representatives of both parties. Each Statement of Work shall contain a detailed description of the content, requirements, schedule,
hours of the services to be provided and other relevant details. Unless a Statement of Work expressly states otherwise, all services
shall be provided at a fixed rate per hour of $195.00 US, and all materials provided at factory cost plus 10%. Aerosonic shall
invoice LG CNS for all amounts due in connection with the services in accordance with Aerosonic’s customary business practices.
LG CNS shall pay all invoiced amounts within thirty (30) days after receipt of the invoice for such amounts, unless an earlier
due date for such amounts is stated in the applicable Statement of Work. All amounts due for services provided under this Agreement
are exclusive of taxes and LG CNS shall be responsible for all sales, use and excise taxes, and any other similar taxes, duties
and charges of any kind imposed by any federal, state, local or foreign governmental entity on any amounts payable by LG CNS under
this Agreement. LG CNS shall be solely responsible for ensuring that the LG CNS EFIS and all related activities, including without
limitation, the services provided to LG CNS by Aerosonic, are in compliance with all applicable laws, regulations, governmental
requirements and permitting requirements. 

 

Future
Marketing Collaboration. The Parties agree to use reasonable efforts to negotiate a
future Sales and Marketing Collaboration Agreement pursuant to which Aerosonic will cooperate with LG CNS on efforts to secure
business opportunities, including, but not limited to, LAH / LCH and KFX programs, on the terms and conditions specified in such
agreement. These opportunities will include all products offered by the parties, whether currently existing or developed in the
future.

 

    	 

    	 

    

 

 

Quotation
for System Integration Lab. The Parties have agreed on a quotation and plans for the development of a System Integration
Lab (“SIL”) by Aerosonic for LG CNS. Any development of a SIL shall be subject to the negotiation and execution
of a definitive agreement between the Parties and the costs shall be in addition to and separate from any payment due under the
this Agreement.

 

Transfer
of EFIS Technology; License Grant to Aerosonic.

 

Purchase
and Sale of EFIS Technology. Effective as of the Transfer Date and subject to Aerosonic’s
receipt of the Transfer Payment (as defined below), Aerosonic hereby sells, transfers, conveys, assigns and delivers to LG CNS,
and LG CNS hereby purchases and acquires from Aerosonic the software and other technology described on Exhibit
A attached to this Agreement, as well as the Intellectual Property Rights (as defined on Exhibit
A) embodied therein (collectively, the “EFIS Technology”). The transfer of the EFIS Technology shall
be effective on the date (the “Transfer Date”) that LG CNS pays to Aerosonic the Transfer Payment in immediately
available funds. LG CNS will not acquire any right, title or interest in or to the EFIS Technology unless and until the Transfer
Payment has been received by Aerosonic. Unless Aerosonic agrees in writing otherwise, the Transfer Date may not occur later than
January 25, 2013. 

 

Purchase
Price. The purchase price for the EFIS Technology shall be $2,300,000 (the “Purchase
Price”), which shall be payable by LG CNS to Aerosonic in accordance to the following schedule plus $200,000 for one
year of Engineering services and support payable in accordance with the following schedule:

 

$200,000 upon execution of this Agreement (the
“Engineering services and support Payment”);

 

$1,553,000 on or before January 25, 2013 (the
“Transfer Payment”);

 

$500,000 on January 25, 2016 (the “First
Deferred Payment”); and

 

$247,000 on January 25, 2017 (the “Second
Deferred Payment” and together with the First Deferred Payment, the “Deferred Payments”).

 

The Purchase Price shall be deemed fully
earned and payable to Aerosonic as of the Effective Date. All payments made by LG CNS to Aerosonic in accordance with this Section
3.2 shall be made in United States dollars in immediately available funds. Aerosonic shall be entitled to recover interest,
which shall accrue at a rate of 10% per annum, on all amounts not paid when due in accordance with the above schedule. The Closing
Payment is not refundable. The Transfer Payment and the Deferred Payments are not contingent on any circumstances, including diligence
or performance of the Acquired Technology. On the Transfer Date, LG CNS shall cause a financial institution reasonably acceptable
to Aerosonic to issue a payment (guarantee) bond  of a face amount equal to the first Deferred Payment of $500,000 naming
Aerosonic as beneficiary, pursuant to which Aerosonic will be permitted to draw down the amount of the Deferred Payment on the
date listed above on which such Deferred Payment is due. On or before January 25, 2016 LG CNS shall cause a financial institution
reasonably acceptable to Aerosonic to issue a payment guarantee bond of a face amount equal to the second Deferred Payment of $247,000
naming Aerosonic as beneficiary, pursuant to which Aerosonic will be permitted to draw down the amount of the Deferred Payment
on the date listed above on which such Deferred Payment is due.

 

Aerosonic is responsible for paying any and all taxes levied
to

Aerosonic in relation to providing the services defined in this
agreement.

 

Aerosonic acknowledges that LG CNS will have to withhold 11%
from the total amount of

(b), (c), (d) invoice related to National TAX Service for the
duration of the agreement.

(Aerosonic need to submit "Application for Entitlement
to Reduced Tax Rate" documents)

 

    	 

    	 

    

 

 

Grant
of License. Effective upon the Transfer Date and without the requirement of further
action by either of the Parties, LG CNS hereby grants to Aerosonic and Aerosonic hereby accepts the grant of a non-exclusive, worldwide,
fully paid, royalty-free, perpetual, transferable and irrevocable right and license (the “Contingent License”)
to use (with the right to sublicense) the EFIS Technology for future development of Stand by EFIS,
including Aerosonic’s OASIS product and derivatives of the OASIS product. Any modifications to, derivative works
of, or enhancements to the EFIS Technology created by or on behalf of Aerosonic pursuant to and within the scope of the Contingent
License, shall be owned by Aerosonic.

 

Representations
and Warranties.

 

Representations
and Warranties by Aerosonic. Aerosonic represents and warrants to LG CNS as follows:

 

Aerosonic has the right, power and
authority to enter into this Agreement and to carry out its obligations hereunder with full power and authority to conduct its
business as it is being conducted, to own or use its assets.

 

Aerosonic is a corporation duly organized,
validly existing and in good standing under the laws in the jurisdiction in which it is organized, and is duly qualified to do
business as a foreign entity and is in good standing under the laws of each other jurisdiction that requires such qualification.

 

This Agreement constitutes the legal,
valid and binding obligations of Aerosonic, enforceable against Aerosonic in accordance with its terms, except as such enforceability
may be limited by bankruptcy laws and other similar laws affecting creditors’ rights generally and by general principles
of equity.

 

The execution, delivery and performance
of this Agreement by Aerosonic has been duly authorized by all necessary corporate action and does not and will not (i) conflict
with, or constitute a breach or default under, its charter documents, any material agreement, contract, commitment or instrument
to which Aerosonic is a party; or (ii) require the consent, approval or authorization of, or notice, declaration, filing or registration
with, any third party or any governmental or regulatory authority.

 

EXCEPT
AS EXPRESSLY SET FORTH IN THIS AGREEMENT, THE EFIS TECHNOLOGY IS TRANSFERRED TO LG CNS BY AEROSONIC ON AN “AS IS” AND
“WHERE IS” BASIS AND AEROSONIC MAKES NO OTHER REPRESENTATIONS OR WARRANTIES, EXPRESS OR IMPLIED, WITH RESPECT TO THE
EFIS TECHNOLOGY, ANY SERVICES CONTEMPLATED BY THIS AGREEMENT OR OTHERWISE, INCLUDING WITHOUT LIMITATION ANY IMPLIED WARRANTIES
OF MERCHANTABILITY, PERFORMANCE, NON-INFRINGEMENT OR FITNESS OR USEFULNESS FOR A PARTICULAR PURPOSE. 

 

Representations
and Warranties by LG CNS. LG CNS represents and warrants to Aerosonic as follows:

 

LG CNS has the right, power and authority
to enter into this Agreement and to carry out its obligations hereunder and to carry out its obligations hereunder with full power
and authority to conduct its business as it is being conducted, to own or use its assets.

 

LG CNS is a corporation duly organized,
validly existing and in good standing under the laws in the jurisdiction in which it is organized, and is duly qualified to do
business as a foreign entity and is in good standing under the laws of each other jurisdiction that requires such qualification.

 

This Agreement constitutes the legal,
valid and binding obligations of LG CNS, enforceable against LG CNS in accordance with its terms, except as such enforceability
may be limited by bankruptcy laws and other similar laws affecting creditors’ rights generally and by general principles
of equity.

 

    	 

    	 

    

 

 

The execution, delivery and performance
of this Agreement by Aerosonic has been duly authorized by all necessary corporate action and does not and will not (i) conflict
with, or constitute a breach or default under, its charter documents, any material agreement, contract, commitment or instrument
to which Aerosonic is a party; or (ii) require the consent, approval or authorization of, or notice, declaration, filing or registration
with, any third party or any governmental or regulatory authority.

 

Term
and Termination.

 

Term.
The term of this Agreement shall commence on the Effective Date and continue in full force and effect for four (4) years (the “Term”),
unless earlier terminated upon mutual agreement of the Parties or pursuant to the terms of this Agreement. 

 

Termination
by Either Party. Either Party shall have the right to terminate this Agreement, prior
to the expiration of the Term, upon the occurrence of any one or more of the following: 

 

The breach or default by the other
Party of any of the terms, obligations, covenants, representations or warranties under this Agreement, which breach or default
is not cured within thirty (30) days after written notice; provided, there shall be no cure period for an incurable breach or default.

 

The other party is declared insolvent
or bankrupt, or makes an assignment for the benefit of creditors, or a receiver is appointed or any proceeding is demanded by,
for or against the other under any provision of the United States Bankruptcy Code or any amendment thereof.

 

Effect
of Termination. In the event of termination or expiration of this Agreement, this Agreement
shall be void and have no further force effect, except that the terms and provisions of Sections 3.3, 4.1(f) 6,
7, 8, and 10 shall survive indefinitely. Notwithstanding anything to the contrary contained in this Agreement,
no party shall be relieved or released from any monetary liability arising prior to the termination or expiration of this Agreement.

 

Confidentiality.

 

Acknowledgements;
Confidential Information. The Parties acknowledge that, in order to successfully perform
their respective duties hereunder, it is necessary for each Party (the “Disclosing Party”) to entrust the other
Party (the “Receiving Party”) and its employees, officers, directors, agents approved consultants and other
designated representatives (collectively, “Representatives”) with certain valuable proprietary information and
knowledge of certain modes of business operation which are essential to the profitable operation of the Disclosing Party and which
give the Disclosing Party a competitive advantage over other firms pursuing related business activities. “Confidential
Information” shall mean any information exchanged between the Parties which is either: (a) marked confidential; (b) accompanied
by correspondence indicating such information is confidential; or (c) orally disclosed and confirmed in writing as confidential
within forty-five (45) days. Confidential Information shall not include (i) information that was already available to the public
or became so through no fault of the receiving Party; (ii) information that is subsequently disclosed to Receiving Party by a third
Party that has the right to disclose it free of any obligations of confidentiality; and (iii) information that was independently
developed by the Receiving Party without reliance on the Confidential Information of the Disclosing Party. The Receiving Party
and its Representatives shall be entitled to disclose Confidential Information if in the opinion of its legal counsel such disclosure
is required to comply with any law, order, decree or, governmental or regulatory request, in which event the Receiving Party shall
promptly notify the Disclosing Party of the disclosure requirement and, if requested, provide reasonable cooperation to the Disclosing
Party in obtaining a protective order or other confidential treatment to protect the confidentiality of the information to be disclosed.

 

    	 

    	 

    

Use
of Confidential Information. All Confidential Information which the Receiving Party
and its Representatives may obtain from the Disclosing Party (whether or not during the period of this Agreement) shall not, without
the prior written consent of the Disclosing Party, be published, disclosed or made accessible by the Receiving Party or any of
its Representatives to any other person either during or after the termination of this Agreement, or used by it, him or her except
in accordance with the terms of this Agreement or as expressly authorized by the Disclosing Party. The Receiving Party agrees to
protect all Confidential Information of the Disclosing Party in its control or possession using methods at least as stringent as
the Receiving Party uses to protect its own confidential information. Except as may be authorized in advance in writing by the
Disclosing Party, the Receiving Party shall grant access to the Confidential Information only to those Representatives involved
in activities relating to the purpose of this Agreement and the Receiving Party shall require such employees to execute and deliver
to the Receiving Party an agreement containing confidentiality and non-disclosure obligations similar to those contained in this
Agreement. Nothing contained in this Agreement or in any other agreement between the Parties or any Representative shall be deemed
to weaken or waive any rights related to the protection of trade secrets or confidential information that either Party may have
under common law or any applicable statutes or rules. 

 

Return
of Confidential Information. Upon expiration or termination of this Agreement, each
Party will promptly return to the other Party or, with the other Party’s written consent, destroy all Confidential Information
received under this Agreement, and all copies, extracts and other objects or items in which such Confidential Information may be
contained or embodied, and certify in writing to the other Party that it has complied with this requirement. 

 

Non-Solicitation.
During the Term and for a period of two (2) years thereafter, neither Party shall, directly or indirectly through another Person
(other than on behalf of and for the benefit of the other Party), (a) induce or attempt to induce any employee or officer
or independent contractor of the other Party to leave the employ of, or terminate its affiliation with, the other Party, or in
any way interfere with the relationship between the other Party and any such Person, (b) hire or seek any business affiliation
with any person who was an employee or officer or independent contractor of the other Party within one (1) year after such person
ceased to be an officer or employee of the other Party, or (c) induce or attempt to induce any customer, supplier, licensee
or other business relation of the other Party to cease doing business with the other Party, reduce the business that it does with
the other Party or in any way interfere with the relationship between any such customer, supplier, licensee or business relation
and the other Party (including, without limitation, making any negative statements or communications concerning the other Party).

 

Insurance.
Each Party shall maintain customary liability insurance to cover its activities, in scope and amounts which are reasonable,
appropriate and customary for similar companies and activities, and shall provide evidence of such coverage upon request from the
other party. Upon request from Aerosonic, LG CNS shall include Aerosonic as an additional insured party under its insurance policies.

 

Miscellaneous.

 

Time
of the Essence. Time is of the essence to each provision of this Agreement and each
performance required thereby.

 

Dispute
Resolution. All disputes, controversies, claims, questions or differences arising between
the Parties in relation to this Agreement, or for breach thereof, which cannot be settled amicably through mutual consultation
between the Parties within sixty (60) days of initial written request by either Party, shall be finally settled by binding arbitration
in Clearwater, Florida pursuant to the rules of the American Arbitration Association (“AAA”). This Agreement
shall control for any conflict between this Agreement and the rules of the AAA. Judgment upon the award of the arbitrators may
be entered in any court having competent jurisdiction according to Section 10.3. All costs associated with such arbitration
shall be equally borne by the Parties, unless otherwise awarded at the discretion of the arbitrator. The arbitrator shall also
have discretion to award the prevailing Party its reasonable attorneys’ fees and costs. Nothing in this Section 9.2
shall prohibit a Party from instituting judicial proceedings (in accordance with Section 9.3) to (a) compel arbitration
or mediation in accordance with this Section 9.2, (b) obtain orders to require witnesses to obey subpoenas issued by the
Arbitrator or as may otherwise be necessary to facilitate the arbitration proceedings or (c) seek injunctive relief, specific performance
or other equitable relief.

 

    	 

    	 

    

 

 

Governing
Law; Jurisdiction and Venue. This Agreement shall be construed under and interpreted
under the Laws of the State of New York, USA, except that questions affecting the construction and effect of any patent shall be
determined by the national law of the country in which the patent has been granted. All disputes not settled under Section 9.3
and arising out of or related to this Agreement will be subject to the exclusive jurisdiction of the New York State Courts (or,
if there is federal jurisdiction, the appropriate United States District Court for the New York, NY geographic area) and the Parties
consent to the personal and exclusive jurisdiction of these courts. Process in any such action or proceeding may be served on any
Party anywhere in the world, including by sending or delivering a copy of the process to the Party to be served at the address
and in the manner provided for the giving of notices in Section 9.5. Nothing in this Section 9.3 will affect the
right of any party to serve legal process in any other manner permitted by law or at equity.

 

Administration.
Each Party will designate one or more individuals to manage this Agreement and ensure compliance with this Agreement. Each Party
shall provide notice to the other Party informing the other Party of the designated individuals. Each Party may change such designated
individuals upon notice to the other Party.

 

Notices.
Any notice required to be given pursuant to the provisions of this Agreement shall be in writing and shall be deemed to have been
given at the earlier of the time when actually received as a consequence of any effective method of delivery, including but not
limited to hand delivery, or delivery by a professional courier service, or the time when sent by certified or registered mail
addressed to the Party for whom intended at the address below. Either Party may change the address(es) given below or elsewhere
in this Agreement at any time by providing the other Party with written notice in accordance with this Section 9.5 at the
address for the other Party specified below, or as subsequently modified.

 

If to AEROSONIC:

 

Aerosonic Corporation

1212   Hercules Ave.

Clearwater, FL 33765

Attention: Mark Perkins

 

With
a copy (which shall not constitute notice) to:

 

Hill, Ward & Henderson, P.A.

101 East Kennedy Boulevard, Suite 3700

Tampa, Florida 33602

Attention: David S. Felman

E-mail: dfelman@hwhlaw.com

 

If to LG CNS:

 

LG CNS Co., Ltd.

20F, Prime Tower #10-1

Hoehyeon-dong,2-ga

Jung-gu, Seoul, 100-725, Korea

Attention: Chong Jae Park

 

Integration.
This Agreement (and any subsequent Statements of Work) constitutes the full understanding between the Parties with reference to
the subject matter hereof, and no statements or agreements by or between the Parties, whether orally or in writing, made prior
to or at the signing hereof (including without limitation the Memorandum of Understanding dated as of October 12, 2012, between
the Parties), shall vary or modify the written terms of this Agreement.

 

    	 

    	 

    

 

 

Amendments.
No amendment or modification hereof shall be valid or binding upon the Parties unless made in writing and signed on behalf of each
Party by an authorized representative.

 

Assignment.
Neither Party shall assign nor otherwise transfer, whether directly or indirectly, in whole or in part this Agreement, voluntarily,
involuntarily or by any other means (except by operation of law including any merger or consolidation, substantial change in ownership
or control of business wherein such assignment or transfer may be freely made), without the prior written consent of the other
Party. This Agreement shall bind the Parties, their successors and their permitted assigns.

 

Advice
of Counsel. Aerosonic and LG CNS have each consulted counsel of their choice regarding
this Agreement, and each acknowledges and agrees that this Agreement shall not be deemed to have been drafted by one Party or another,
and that normal rules of construction, to the effect that ambiguities are to be resolved against the drafting Party, shall not
apply to this Agreement or to any amendments, modifications or exhibits to this Agreement. Without limiting the foregoing, the
provisions herein regarding limitation of liability, damages and warranties allocate the risks of this Agreement between the parties.
This allocation is reflected in the economic terms of this Agreement and is an essential element of the basis of the bargain between
the parties.

 

Severability.
If any provisions of this Agreement are or shall come into conflict with the laws or regulations of any jurisdiction or any governmental
entity having jurisdiction over the Parties or this Agreement, those provisions shall be deemed automatically deleted, if such
deletion is allowed by relevant law, and the remaining terms and conditions of this Agreement shall remain in full force and effect.
If such a deletion is not so allowed or if such a deletion leaves terms thereby made clearly illogical or inappropriate in effect,
the Parties agree to substitute new terms as similar in effect to the present terms of this Agreement as may be allowed under the
applicable laws and regulations.

 

Independent
Contractors. The relationship of the Parties
established by this Agreement is that of independent contractors. Nothing in this Agreement shall be construed to create any other
relationship between Aerosonic and LG CNS. Neither Party shall have any right, power or authority to assume, create or incur any
expense, liability or obligation, express or implied, on behalf of the other Parties.

 

Force
Majeure. In the event either Party hereto is prevented from or delayed in the performance
of any of its obligations hereunder by reason of acts of God, war, strikes, riots, storms, fires, or any other cause whatsoever
beyond the reasonable control of the Party, the Party so prevented or delayed shall be excused from the performance of any such
obligation to the extent and during the period of such prevention or delay.

 

Waiver.
No failure or delay by a Party in exercising any of its rights or remedies hereunder shall operate as a waiver thereof, nor shall
any single or partial exercise of any such right or remedy preclude any other or further exercise thereof of any other right or
remedy. The rights and remedies of the Parties provided in this Agreement are cumulative and not exclusive of any rights or remedies
provided by law.

 

Headings.
Headings included herein are for convenience only, do not form a part of this Agreement and shall not be used in any way to construe
or interpret this Agreement.

 

Counterparts
and Execution. This Agreement may be executed in counterparts, each of which shall
be deemed an original, but both of which together shall constitute one and the same instrument. Signatures transmitted by facsimile,
PDF or other electronic means by authorized agents of either Party of this Agreement shall be considered as having the same effect
as original signatures.

 

Public
Announcements. Neither Party shall make any public announcement of, or otherwise disclose
to a third party, the existence of this Agreement, the terms and conditions set forth in this Agreement or any matters relating
to this Agreement, except as mutually agreed in writing or as required by disclosure obligations arising under law.

 

Currency.
All payments required under this Agreement or any Statement of Work must be made in United States Dollars. 

 

    	 

    	 

    

 

No
Third Party Beneficiaries. The terms of this Agreement are intended solely for the
benefit of each of the Parties, and their successors and permitted assigns and it is not the intention of the Parties to confer
third-party beneficiary rights upon any other person.

 

[The remainder of the page is intentionally
blank; Signatures follow on next page]

 

IN WITNESS WHEREOF, the parties hereto have
caused this Agreement to be executed as of the date written above.

 

 

	 	AEROSONIC CORPORATION
	 	 	 
	 	By:	 
	 	 	Name: Mark Perkins
	 	 	Title: Executive Vice President
	 	 	 
	 	LG CNS CO., LTD.
	 	 	 
	 	By:	 
	 	 	Name: Chong Jae Park
	 	 	Title: Derector, Defense Business

 

    	 

    	 

    

 

Exhibit A

EFIS Technology

 

EFIS Technology:

 

Software:  Aerosonic will provide source code for the v:T4.3.05
version of “Experimental” code including all relevant drivers and graphics libraries.

 

Mechanical: Aerosonic will provide Solidworks 3D models and
Bills of Material  of the Gen 2 hardware configuration for the 9.4 Landscape display configuration that exist at the time
of the transfer.

 

Hardware: Aerosonic will deliver Gen1 hardware and Gen2 hardware
prototypes as the exist today.

 

Electrical: Aerosonic will provide schematics, layout drawings,
Gerber files and parts lists for the Gen 2, 9.4 Landscape configuration that exists at the time of the transfer.

 

Documents: Aerosonic will deliver the following Software Life
Cycle (SLC) Documents defined for the Gen 2 hardware and “Certified” (version T4.3.05 with reduced functionality) of
the software at the level of revision that exists at the time of the transfer:

 

Plan for Software Aspects of Certification*

Software Development Plan*

Software Verification Plan*

Software Configuration Management Plan*

Software Quality Assurance Plan*

Software Requirements Standard

Software Coding Standards

Software Requirements Document

Software Design Document – Core Library

Hardware Requirements Document (Preliminary)

Interface Control Document (Visio Only)*

Traceability Matrix (Draft Only)

Software Build Procedure

Gen 1 Acceptance Test Procedure

Marketing Requirements Document

System Requirements Document*

Software design Description

 

* Will be provided at the time of contract signing and payment
as described in Section 3.2 a.

 

The balance of documents will not be delivered
until formal IP Transfer and receipt of payment as described in Section 3.2 b.

 

“Intellectual Property Rights” means (a)
patents, patent disclosures and inventions (whether patentable or not); (b) copyrights and copyrightable works (including computer
programs), mask works and rights in data and databases; (c) trade secrets, know-how and other confidential information; and (d)
all other intellectual property rights, in each case whether registered or unregistered and including all applications for, and
renewals or extensions of, such rights, and all similar or equivalent rights or forms of protection provided by applicable law
in any jurisdiction throughout the world; provided that, Intellectual Property Rights shall not include trademarks, service
marks, trade dress, logos, trade names, corporate names or other similar indicia of origin.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00216-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00216-of-00352.parquet"}]]